50 and older, any sex, with Neovascular Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline in Best Corrected Visual Acuity (BCVA)Primary· Baseline and Week 8
The VA was assessed using original series ETDRS charts or 2702 series number charts.
Group
Value
95% CI
SB15 (Proposed Aflibercept Biosimilar)
6.7
± 0.56
Eylea (Aflibercept)
6.6
± 0.57
Adverse events — posted to ClinicalTrials.gov
Time frame: Overall Period (56 weeks).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, Pharmacokinetics (PK), and immunogenicity of SB15 compared to Eylea® in subjects with neovascular AMD.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Neovascular Age-related Macular Degeneration
Currently open trials in the same condition.
NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
· Phase 2
· recruiting
NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
· Phase 3
· recruiting
NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients
· EARLY_PHASE1
· recruiting
NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
· recruiting
NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R
· Phase 3
· active not recruiting
Other Samsung Bioepis Co., Ltd. trials
Trials by the same sponsor.
NCT06176963 — A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
· Phase 2
· completed
NCT05510063 — Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic
· Phase 4
· completed
NCT04967508 — A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasi
· Phase 3
· completed
NCT04772274 — A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of Am
· Phase 1
· completed
NCT04664959 — A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Bioepis Co., Ltd.
Last refreshed: 5 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04450329.